Cirrhosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
The following therapies are under trial: | The following therapies are under trial: | ||
*[[Obeticholic acid]] (OCA) for patients with [[primary biliary cirrhosis]].<ref name="pmid21297469">{{cite journal| author=Lindor KD| title=Farnesoid X receptor agonists for primary biliary cirrhosis. | journal=Curr Opin Gastroenterol | year= 2011 | volume= 27 | issue= 3 | pages= 285-8 | pmid=21297469 | doi=10.1097/MOG.0b013e32834452c8 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21297469 }} </ref> | *[[Obeticholic acid]] (OCA) for patients with [[primary biliary cirrhosis]].<ref name="pmid21297469">{{cite journal| author=Lindor KD| title=Farnesoid X receptor agonists for primary biliary cirrhosis. | journal=Curr Opin Gastroenterol | year= 2011 | volume= 27 | issue= 3 | pages= 285-8 | pmid=21297469 | doi=10.1097/MOG.0b013e32834452c8 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21297469 }} </ref> | ||
*Boehringer Ingelheim’s investigational direct-acting antiviral compounds: [[BI 201335]] ([[protease inhibitor]] plus [[BI 207127]] ([[polymerase inhibitor]]) | *Boehringer Ingelheim’s investigational direct-acting antiviral compounds: [[BI 201335]] ([[protease inhibitor]]) plus [[BI 207127]] ([[polymerase inhibitor]]) for the treatment of [[Hepatitis C]] induced Cirrhosis. | ||
==Reference== | ==Reference== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 19:14, 6 September 2012
|
Cirrhosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case studies |
|
Cirrhosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Cirrhosis future or investigational therapies |
|
Risk calculators and risk factors for Cirrhosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-In-Chief: Ujjwal Rastogi, M.B.B.S. [2]
Overview
Future or Investigational Therapies
The following therapies are under trial:
- Obeticholic acid (OCA) for patients with primary biliary cirrhosis.[1]
- Boehringer Ingelheim’s investigational direct-acting antiviral compounds: BI 201335 (protease inhibitor) plus BI 207127 (polymerase inhibitor) for the treatment of Hepatitis C induced Cirrhosis.
Reference
- ↑ Lindor KD (2011). "Farnesoid X receptor agonists for primary biliary cirrhosis". Curr Opin Gastroenterol. 27 (3): 285–8. doi:10.1097/MOG.0b013e32834452c8. PMID 21297469.